Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
Genet. mol. res. (Online) ; 4(4): 771-782, 2005. tab
Article Dans Anglais | LILACS | ID: lil-444844

Résumé

Several studies have reported that the genes involved in DNA repair and in the maintenance of genome integrity play a crucial role in protecting against mutations that lead to cancer. Epidemiologic evidence has shown that the inheritance of genetic variants at one or more loci results in a reduced DNA repair capacity and in an increased risk of cancer. Polymorphisms have been identified in several DNA repair genes, such as XRCC1, XPD, XRCC3, and RAD51, but the influence of specific genetic variants on repair phenotype and cancer risk has not yet been clarified. This was a case-control study design with three case groups: 53 women with breast cancer and family history; 33 women with sporadic breast cancer; 175 women with no breast cancer but with family history. The control group included 120 women with no breast cancer and no family history. The PCR-RFLP method was used to analyze the XRCC1-Arg399Gln, XPD-Lys751Gln, XRCC3-Thr241Met, and RAD51-G135C polymorphisms. No statistically significant differences were found between the case groups and the control group for any of the polymorphisms analyzed, and also between the breast cancer and family history group and the sporadic breast cancer group. Sample sizes of women with breast cancer, whether familial or sporadic, were insufficient to show any small true differences between the groups, but we have to consider that currently there is no clear consensus with respect to the association of these polymorphisms with breast cancer risk. Considering the data available, it can be conjectured that if there is any risk association between these single-nucleotide polymorphisms and breast cancer, this risk will probably be minimal. The greater the risk associated with cancer, the smaller the sample size required to demonstrate this association, and the data of different studies are usually, therefore, more concordant.


Sujets)
Humains , Femelle , Adulte , Tumeurs du sein/génétique , Polymorphisme génétique/génétique , Prédisposition génétique à une maladie/génétique , Réparation de l'ADN/génétique , Brésil , Loi du khi-deux , Études cas-témoins , Facteurs de risque , Marqueurs génétiques/génétique , Polymorphisme de restriction , Réaction de polymérisation en chaîne/méthodes
2.
Braz. j. med. biol. res ; 35(4): 425-430, Apr. 2002. ilus, tab
Article Dans Anglais | LILACS | ID: lil-309198

Résumé

The c-myc protein is known to regulate the cell cycle, and its down-regulation can lead to cell death by apoptosis. The role of c-myc protein as an independent prognostic determinant in cervical cancer is controversial. In the present study, a cohort of 220 Brazilian women (mean age 53.4 years) with FIGO stage I, II and III (21, 28 and 51 percent, respectively) cervical squamous cell carcinomas was analyzed for c-myc protein expression using immunohistochemistry. The disease-free survival and relapse-rate were analyzed using univariate (Kaplan-Meier) survival analysis for 116 women who completed the standard FIGO treatment and were followed up for 5 years. Positive c-myc staining was detected in 40 percent of carcinomas, 29 percent being grade 1, 9 percent grade 2, and 2 percent grade 3. The distribution of positive c-myc according to FIGO stage was 19 percent (17 women) in stage I, 33 percent (29) in stage II, and 48 percent (43) in stage III of disease. During the 60-month follow-up, disease-free survival in univariate (Kaplan-Meier) survival analysis (116 women) was lower for women with c-myc-positive tumors, i.e., 60.5, 47.5 and 36.6 percent at 12, 36, and 60 months, respectively (not significant). The present data suggest that immunohistochemical demonstration of c-myc does not possess any prognostic value independent of FIGO stage, and as such is unlikely to be a useful prognostic marker in cervical squamous cell carcinoma


Sujets)
Humains , Femelle , Adulte , Adulte d'âge moyen , Marqueurs biologiques tumoraux , Carcinome épidermoïde , Protéines proto-oncogènes c-myc , Tumeurs du col de l'utérus , Sujet âgé de 80 ans ou plus , Études de cohortes , Survie sans rechute , Études de suivi , Immunohistochimie , Valeur prédictive des tests , Pronostic
4.
Rev. bras. ginecol. obstet ; 11(5): 87-90, maio 1989. tab, ilus
Article Dans Portugais | LILACS | ID: lil-93790

Résumé

Os autores avaliam a termografia de placa realizada em controles periódicos e empregada através de uma metodologia de interpretaçäo diagnóstica adequada na detecçäo do carcinoma "in situ" de mama, quando entäo, praticamente, näo há manifestaçöes clínicas da sua presença. Baseando-se no diagnóstico angiotermográfico, foram realizadas 127 biópsias da mama em 82 mulheres, sendo 45 bilaterais. O estudo histológico revelou no total de 16 carcinomas, sendo 15 "in situ" e um microinvasor, sendo, em três casos, bilaterais. Destes seis eram ductais e nove lobulares. Foram diagnosticadas, ainda, cinco hiperplasias lobulares atípicas. Desta forma, podemos concluir que a termografia de placa é um método propedêutico eficiente no diagnóstico do carcinoma "in situ" da mama


Sujets)
Adulte , Humains , Femelle , Tumeurs du sein/diagnostic , Épithélioma in situ/diagnostic , Thermographie
SÉLECTION CITATIONS
Détails de la recherche